NO753447L - - Google Patents
Info
- Publication number
- NO753447L NO753447L NO753447A NO753447A NO753447L NO 753447 L NO753447 L NO 753447L NO 753447 A NO753447 A NO 753447A NO 753447 A NO753447 A NO 753447A NO 753447 L NO753447 L NO 753447L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- hydrogen
- biguanide
- aryl
- alkylene
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 22
- 150000004283 biguanides Chemical class 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 229940123208 Biguanide Drugs 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229940120124 dichloroacetate Drugs 0.000 claims description 12
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 10
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- -1 alkali metal dichloroacetate Chemical class 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940080263 sodium dichloroacetate Drugs 0.000 description 3
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 3
- LHIYNDNMZPWLRE-UHFFFAOYSA-N 3-(diaminomethylidene)-1,1-dimethylguanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.CN(C)C(=N)NC(N)=N LHIYNDNMZPWLRE-UHFFFAOYSA-N 0.000 description 2
- RXOKINPQLBNYLE-UHFFFAOYSA-N 3-(diaminomethylidene)-1,1-dimethylguanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.CN(C)C(=N)NC(N)=N RXOKINPQLBNYLE-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- INDCLWZUJYYHJR-UHFFFAOYSA-N OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.NC(=N)NC(=N)NC(C)C1=CC=CC=C1 Chemical compound OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.NC(=N)NC(=N)NC(C)C1=CC=CC=C1 INDCLWZUJYYHJR-UHFFFAOYSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GZICHOYZUFCPBQ-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(3-methylbutyl)guanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.CC(C)CCN=C(N)N=C(N)N GZICHOYZUFCPBQ-UHFFFAOYSA-N 0.000 description 1
- ADLZEJVNQRDUFO-UHFFFAOYSA-N 1-(diaminomethylidene)-2-pentylguanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.CCCCCN=C(N)N=C(N)N ADLZEJVNQRDUFO-UHFFFAOYSA-N 0.000 description 1
- QJYIDVVROOIWCI-UHFFFAOYSA-N 1-(diaminomethylidene)-2-pentylguanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.CCCCCN=C(N)N=C(N)N QJYIDVVROOIWCI-UHFFFAOYSA-N 0.000 description 1
- WWPLZCSGXJEVCX-UHFFFAOYSA-N 2-butyl-1-(diaminomethylidene)guanidine;2,2-dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl.OC(=O)C(Cl)Cl.CCCCNC(=N)NC(N)=N WWPLZCSGXJEVCX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- KKLWSPPIRBIEOV-UHFFFAOYSA-N [n'-(n'-butylcarbamimidoyl)carbamimidoyl]azanium;chloride Chemical compound Cl.CCCCN=C(N)N=C(N)N KKLWSPPIRBIEOV-UHFFFAOYSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- TYZDRHAKWOGSHU-UHFFFAOYSA-N azanium;2,2-dichloroacetate Chemical compound [NH4+].[O-]C(=O)C(Cl)Cl TYZDRHAKWOGSHU-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1369774A CH602612A5 (da) | 1974-10-11 | 1974-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO753447L true NO753447L (da) | 1976-04-13 |
Family
ID=4394567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO753447A NO753447L (da) | 1974-10-11 | 1975-10-10 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4028402A (da) |
| JP (1) | JPS51125718A (da) |
| AR (1) | AR209457A1 (da) |
| AT (1) | AT343676B (da) |
| BE (1) | BE834369A (da) |
| BR (1) | BR7506595A (da) |
| CA (1) | CA1053258A (da) |
| CH (1) | CH602612A5 (da) |
| CU (1) | CU34371A (da) |
| DD (1) | DD123322A5 (da) |
| DE (1) | DE2542598A1 (da) |
| DK (1) | DK140834B (da) |
| ES (1) | ES441673A1 (da) |
| FI (1) | FI752626A (da) |
| FR (1) | FR2287221A1 (da) |
| GB (1) | GB1473256A (da) |
| IE (1) | IE41807B1 (da) |
| IL (1) | IL48116A (da) |
| LU (1) | LU73557A1 (da) |
| NL (1) | NL7511890A (da) |
| NO (1) | NO753447L (da) |
| PH (1) | PH12279A (da) |
| PL (1) | PL95259B1 (da) |
| SE (1) | SE7511357L (da) |
| SU (1) | SU572200A3 (da) |
| ZA (1) | ZA755861B (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2401898A1 (fr) * | 1977-09-05 | 1979-03-30 | Aec Chim Organ Biolog | Nouveau sel de l'acide patoique |
| US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| WO1998027982A1 (fr) | 1996-12-24 | 1998-07-02 | Sumitomo Pharmaceuticals Co., Ltd. | Composition contenant de l'acide ascorbique |
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| DE19926233C1 (de) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
| DE19940130A1 (de) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| US7169407B1 (en) | 1999-10-06 | 2007-01-30 | Toshio Miyata | Carbonyl stress-decreasing agent |
| US20080076811A1 (en) * | 2000-01-21 | 2008-03-27 | Bork Balkan | Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents |
| DE60137216D1 (de) * | 2000-03-31 | 2009-02-12 | Prosidion Ltd | Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention |
| FR2809310B1 (fr) | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
| JP2005097117A (ja) * | 2000-06-30 | 2005-04-14 | Chugai Pharmaceut Co Ltd | 糖尿病治療剤 |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| CA2424475A1 (en) * | 2000-10-27 | 2002-05-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders |
| US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| JP2005504766A (ja) * | 2001-08-16 | 2005-02-17 | プロバイオドラッグ アーゲー | プロリンエンドペプチダーゼ阻害剤の、細胞内シグナルカスケード依存性イノシトール（１，４，５）トリホスフェート濃度調節への使用。 |
| US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| DE20220238U1 (de) | 2002-02-28 | 2003-05-08 | Probiodrug AG, 06120 Halle | Glutaminyl basierte DPIV Inhibitoren |
| US20030232761A1 (en) * | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20040033051A1 (en) * | 2002-08-16 | 2004-02-19 | Ip Kiril Kun Wan | Method and system for producing and displaying visual presentations which inhibit off-screen duplication |
| EP1543023B1 (en) * | 2002-09-18 | 2010-03-17 | Prosidion Limited | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| US20040058876A1 (en) * | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| KR20100106630A (ko) | 2003-05-05 | 2010-10-01 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| BRPI0415409A (pt) * | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US20100099721A1 (en) * | 2003-11-03 | 2010-04-22 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
| BRPI0507485A (pt) | 2004-02-05 | 2007-07-10 | Probiodrug Ag | inibidores novos de glutaminil ciclase |
| US8058312B2 (en) * | 2007-01-29 | 2011-11-15 | Hanall Biopharma Co., Ltd. | N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| WO2008097861A2 (en) * | 2007-02-02 | 2008-08-14 | Braincells, Inc. | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
| KR101226669B1 (ko) * | 2007-09-21 | 2013-01-25 | 한올바이오파마주식회사 | Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물 |
| WO2009088220A2 (ko) * | 2008-01-08 | 2009-07-16 | Hanall Pharmaceutical Company. Ltd | Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
| PL2303838T3 (pl) * | 2008-06-26 | 2014-07-31 | Laboratorios Silanes S A De C V | Nowa sól glicynianowa metforminy do kontroli glukozy we krwi |
| WO2010146604A2 (en) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Processes for preparing metformin hydrochloride |
| WO2011049400A2 (ko) * | 2009-10-23 | 2011-04-28 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물 |
| KR101324283B1 (ko) | 2010-04-27 | 2013-11-01 | 한올바이오파마주식회사 | 바이구아나이드 화합물의 신규 염, 그의 제조방법, 그를 포함하는 약제학적 조성물 |
| WO2018060962A2 (en) | 2016-09-30 | 2018-04-05 | Laboratorios Silanes S.A. De C.V. | Metformin amino acid compounds and methods of using the same |
| MX2019003725A (es) | 2016-09-30 | 2019-08-12 | Laboratorios Silanes S A De C V | Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma. |
| CN107118130A (zh) * | 2017-05-11 | 2017-09-01 | 杜剑平 | 一类治疗肿瘤的药物化合物及其应用 |
| CN106986791A (zh) * | 2017-05-11 | 2017-07-28 | 杜剑平 | 一种治疗肿瘤的药物化合物及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3179562A (en) * | 1961-08-23 | 1965-04-20 | Du Pont | Treatment of diabetes with alpha, alpha substituted acetic acid derivatives |
-
1974
- 1974-10-11 CH CH1369774A patent/CH602612A5/xx not_active IP Right Cessation
-
1975
- 1975-09-15 ZA ZA00755861A patent/ZA755861B/xx unknown
- 1975-09-17 IL IL48116A patent/IL48116A/xx unknown
- 1975-09-19 FI FI752626A patent/FI752626A/fi not_active Application Discontinuation
- 1975-09-24 DE DE19752542598 patent/DE2542598A1/de not_active Withdrawn
- 1975-10-06 IE IE2184/75A patent/IE41807B1/en unknown
- 1975-10-08 US US05/620,525 patent/US4028402A/en not_active Expired - Lifetime
- 1975-10-08 PH PH17640A patent/PH12279A/en unknown
- 1975-10-08 CU CU7534371A patent/CU34371A/es unknown
- 1975-10-09 BR BR7506595*A patent/BR7506595A/pt unknown
- 1975-10-09 CA CA237,343A patent/CA1053258A/en not_active Expired
- 1975-10-09 SU SU7502178502A patent/SU572200A3/ru active
- 1975-10-09 NL NL7511890A patent/NL7511890A/xx not_active Application Discontinuation
- 1975-10-09 FR FR7530907A patent/FR2287221A1/fr not_active Withdrawn
- 1975-10-09 LU LU73557A patent/LU73557A1/xx unknown
- 1975-10-09 JP JP50121432A patent/JPS51125718A/ja active Pending
- 1975-10-09 SE SE7511357A patent/SE7511357L/xx unknown
- 1975-10-10 ES ES441673A patent/ES441673A1/es not_active Expired
- 1975-10-10 NO NO753447A patent/NO753447L/no unknown
- 1975-10-10 DD DD188797A patent/DD123322A5/xx unknown
- 1975-10-10 BE BE160823A patent/BE834369A/xx unknown
- 1975-10-10 DK DK457475AA patent/DK140834B/da unknown
- 1975-10-10 GB GB4161175A patent/GB1473256A/en not_active Expired
- 1975-10-10 PL PL1975183923A patent/PL95259B1/pl unknown
- 1975-10-10 AT AT776375A patent/AT343676B/de active
- 1975-10-11 AR AR260639A patent/AR209457A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| DK457475A (da) | 1976-04-12 |
| JPS51125718A (en) | 1976-11-02 |
| IE41807L (en) | 1976-04-11 |
| SU572200A3 (ru) | 1977-09-05 |
| CA1053258A (en) | 1979-04-24 |
| PH12279A (en) | 1978-12-12 |
| DD123322A5 (da) | 1976-12-12 |
| SE7511357L (sv) | 1976-04-12 |
| DK140834C (da) | 1980-04-28 |
| DE2542598A1 (de) | 1976-04-22 |
| AR209457A1 (es) | 1977-04-29 |
| IL48116A (en) | 1979-07-25 |
| CU34371A (es) | 1979-06-01 |
| FI752626A (da) | 1976-04-12 |
| BR7506595A (pt) | 1976-08-17 |
| ATA776375A (de) | 1977-10-15 |
| DK140834B (da) | 1979-11-26 |
| BE834369A (fr) | 1976-04-12 |
| PL95259B1 (pl) | 1977-10-31 |
| CH602612A5 (da) | 1978-07-31 |
| AU8497775A (en) | 1977-03-24 |
| GB1473256A (en) | 1977-05-11 |
| US4028402A (en) | 1977-06-07 |
| FR2287221A1 (fr) | 1976-05-07 |
| ZA755861B (en) | 1976-08-25 |
| IL48116A0 (en) | 1975-11-25 |
| ES441673A1 (es) | 1977-04-01 |
| IE41807B1 (en) | 1980-03-26 |
| NL7511890A (nl) | 1976-04-13 |
| LU73557A1 (da) | 1977-05-24 |
| AT343676B (de) | 1978-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO753447L (da) | ||
| CS272241B2 (en) | Method of crystalline citromycindihydrate production | |
| FR2629715A1 (fr) | Derives de l'adenosine, leur procede de preparation et leur utilisation en therapeutique | |
| JP7160946B2 (ja) | （チオ）ニコチンアミドリボフラノシド塩および組成物、製造方法、およびそれらの使用 | |
| US2446102A (en) | Complex salts of streptomycin and process for preparing same | |
| US4914208A (en) | Optically active salts of a substituted thiazolidine-4-carboxylate and 3-chloro-2-hydroxypropyltrimethyl ammonium, their preparation and use | |
| EP0213785A1 (en) | Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl)ethylamine | |
| SU1329616A3 (ru) | Способ получени оптически активного карнитиннитрилхлорида | |
| US2229187A (en) | Amino-alcohol and a process for its production | |
| US3397231A (en) | Refining of alpha-6-deoxy-5-oxytetracycline | |
| DE1946829A1 (de) | Oxadiazolderivate | |
| US4352759A (en) | Recovery of high purity N-acyl taurine in high yield | |
| US4346045A (en) | Process for resolving DL-S-benzoyl-β-mercaptoisobutyric acid, and products obtained | |
| EP0050521B1 (en) | Preparation of insecticidal optically active isovalerate esters | |
| US1989093A (en) | Amino alcohols and the production thereof | |
| WO2002012177A1 (en) | Composition of metformin with succinic acid or salts thereof and method for treating diabetes | |
| JP2507505B2 (ja) | セファロスポリン誘導体の新規製造方法 | |
| Levene | BENZYLIDENE-ETHYL-CHITOSAMINATE AND BENZYLIDENE-ETHYL-DIAZOGLUCONATE (MANNONATE) | |
| CH594650A5 (en) | Antiinflammatory (1,2)-benzothiazine derivs. prepn. | |
| NO770524L (no) | Fremgangsm}te ved spaltning av alanin-racemater | |
| EP1363882A1 (en) | 3-(3-amidinophenyl)-5- ( 1-(1-(-iminoethyl)-4-piperidyl amino)methyl]benzoic acid dihydrochloride and process for preparing the same | |
| US3221011A (en) | Dibenzazepine derivatives | |
| Jacobs et al. | THE QUATERNARY SALTS OF HEXAMETHYLENE-TETRAMINE. IV. MONOHALOGENACYLATED SIMPLE AMINES, UREAS, AND URETHANES, AND THE HEXAMETHYLENETETRAMINIUM SALTS DERIVED THEREFROM. | |
| US2781347A (en) | 3-acylamidorhodanines and process for preparation | |
| US2512525A (en) | Production of an alkali metal salt of sulfanilamidothiazole |